Laboratory Corp. of America Holdings
) announced the commercial launch of Prosigna Breast Cancer
Prognostic Gene Signature Assay. This U.S. Food and Drug
Administration (FDA)-approved product has been developed by
NanoString Technologies, Inc.
). Following the announcement, the share price of LH inched up
The Prosigna assay is an in-vitro diagnostic tool and is based
on the PAM50 gene signature. It utilizes gene expression data and
provides a risk category and numerical score for assessment of
the risk of distant recurrence at 10 years in postmenopausal
women with node-negative (Stage I or II) or node-positive (Stage
II), Hormone Receptor-Positive (HR+) breast cancer. The
Prosigna score is indicated in patients who have undergone
surgery along with locoregional treatment.
The Prosigna assay was researched upon extensively in two
independent clinical studies. The results of the studies
indicated successful performance of the product. The Prosigna
score offered substantial prognostic information and greater
prognostic clarity as compared with other predictive breast
cancer assays such as the Oncotype Dx Breast Cancer Assay.
Laboratory Corp. values its association with this new-age
prognostic test. The company expects the Prosigna test to make
monitoring and treatment of breast cancer recurrence easier for
physicians, when used in combination with other clinical and
In Dec 2013, NanoString had announced the adoption of the
Prosigna Assay by ARUP Laboratories, LH and
), three major U.S. laboratories and cancer centers. Laboratory
Corp. is the first center that has introduced the product at a
Clinical Diagnostics is an important operating segment within
LH. It has contributed nearly 94.1% to the company's total
revenue, for nine months in 2013. We believe the market
availability of the Prosigna assay will further strengthen
Laboratory Corp.'s suite of diagnostic tests and accelerate core
organic growth for the company.
Currently, LH has a Zacks Rank #5 (Strong Sell). A
better-ranked stock in the medical/dental supplies industry is
Align Technology Inc.
) with a Zacks Rank #1 (Strong Buy).
ALIGN TECH INC (ALGN): Free Stock Analysis
QUEST DIAGNOSTC (DGX): Free Stock Analysis
LABORATORY CP (LH): Free Stock Analysis
NANOSTRING TECH (NSTG): Free Stock Analysis
To read this article on Zacks.com click here.